-+ 0.00%
-+ 0.00%
-+ 0.00%

Monopar adds ex-KalVista CCO Nicole Sweeny to board

PUBT·07/20/2026 12:02:36
Listen to the news
Monopar adds ex-KalVista CCO Nicole Sweeny to board
  • Monopar added former KalVista Chief Commercial Officer Nicole Sweeny to its board, elected at the June 22, 2026 annual meeting.
  • Commercial team expanded with Sharon Funk named SVP, Sales and Marketing; she most recently supported Avadel’s LUMRYZ commercialization.
  • Daniel Olmstead appointed SVP, Market Access, Distribution and Patient Services; he most recently supported launches at Ardelyx and Akebia.
  • Moves support launch readiness for Wilson disease drug ALXN1840; NDA submission targeted for mid-2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607200800PRIMZONEFULLFEED9763606) on July 20, 2026, and is solely responsible for the information contained therein.